Firouzabadi et al. had investigated the role of ACE2 G8790A variant against selective serotonin reuptake inhibitors (SSRIs) in a randomized control trial of the Iranian population who had been newly diagnosed with major depressive disorder and completed 6 weeks of treatment with sertraline or fluoxetine. This evidence concerns the gene ACE2 and major depressive disorder.